Patents by Inventor Joshua Ayers

Joshua Ayers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • -pyridino containing compounds for the use in the treatment of CNS pathologies
    Patent number: 8546415
    Abstract: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: October 1, 2013
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran
  • BIS-PYRINDINO CONTAINING COMPOUNDS FOR THE USE IN THE TREATMENT OF CNS PATHOLOGIES
    Publication number: 20100152237
    Abstract: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.
    Type: Application
    Filed: February 26, 2010
    Publication date: June 17, 2010
    Applicant: University of Kentucky Research Foundation
    Inventors: Peter A. CROOKS, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran
  • Bis-pyridino containing compounds for the use in the treatment of CNS pathologies
    Publication number: 20080287490
    Abstract: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.
    Type: Application
    Filed: July 17, 2008
    Publication date: November 20, 2008
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peter A. Crooks, Linda P. Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran
  • Bis-pyridino containing compounds for the use in the treatment of CNS pathologies
    Publication number: 20050261334
    Abstract: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.
    Type: Application
    Filed: January 3, 2005
    Publication date: November 24, 2005
    Inventors: Peter Crooks, Linda Dwoskin, Joshua Ayers, Vladimir Grinevich, Sangeetha Sumithran